An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
|Videos|September 19, 2022
Dr. Shore on next steps with PARP inhibitors in prostate cancer
Author(s)Urology Times staff
Advertisement
Neal D. Shore, MD, discusses what’s on the horizon with PARP inhibitors in the treatment paradigm for patients with prostate cancer. Shore is medical director for the Carolina Urologic Research Center and chief medical officer, Surgical Oncology and Urology, for Genesis Care (US).
Advertisement
Related to this article
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
2026 AUA/SUO NMIBC guideline: Key updates for clinical practice
3
Decipher may help identify ADT benefit in intermediate-risk prostate cancer
4
AUA South Central Section Meeting: Mark D. Tyson, II, MD, MPH, recaps data in NMIBC
5